Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;99(8):1037-44.
doi: 10.1136/bjophthalmol-2014-305768. Epub 2015 Feb 23.

Prevalence of age-related macular degeneration in the Republic of Ireland

Affiliations

Prevalence of age-related macular degeneration in the Republic of Ireland

Kwadwo Owusu Akuffo et al. Br J Ophthalmol. 2015 Aug.

Abstract

Background: Age-related macular degeneration (AMD) remains the most common cause of visual loss among subjects over 50 years of age in the developed world. The Irish Longitudinal study on Ageing (TILDA) is a population-based study of subjects aged 50 years or older, designed to investigate factors that influence ageing, and has enabled this investigation of the prevalence of AMD in the Republic of Ireland (ROI).

Methods: Data collected from a nationally representative sample of community-living older adults aged 50 years and over in ROI over the period November 2009 to July 2011. 5035 participants attended the TILDA health centre for assessment. Retinal photographs were obtained in 4859 of these participants. Retinal grading was performed in a masked fashion using a modified version of the International Classification and Grading System for AMD.

Results: Adjusting for lower response rates among older subjects, the estimated overall prevalence of any AMD was 7.2% (95% CI 6.5% to 7.9%) in the population aged 50 years or older. The estimated prevalence of early AMD was 6.6% (95% CI 5.9% to 7.3%), and the estimated prevalence of late AMD was 0.6% (95% CI 0.4% to 0.8%). Statistically significant associations with AMD included increasing age and family history of the condition.

Conclusions: This is the first study to provide prevalence estimates of AMD in ROI and will inform eye care professionals and policymakers involved in the delivery and planning of care for those afflicted with this condition.

Keywords: Epidemiology; Imaging; Macula; Public health; Vision.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A total of 8175 participants aged 50 years or older completed the Irish Longitudinal study on Ageing (TILDA) baseline (wave 1) interview. Health assessments were conducted in clinical centres in Dublin and Cork, Republic of Ireland. Participants who refused or were unable to attend clinical centres were given the option of a home-based clinical assessment. Home-based clinical assessment did not include retinal photography. Retinal photographs were taken at the clinical centres using the NIDEK AFC-210 camera. Subjects with no photographs were either due to the following reasons: unable, unwilling and technical failure. Photographs were judged as ungradable based on photographic quality.

References

    1. Kelliher C, Kenny D, O'Brien C. Trends in blind registration in the adult population of the Republic of Ireland 1996–2003. Br J Ophthalmol 2006;90:367–71. 10.1136/bjo.2005.075861 - DOI - PMC - PubMed
    1. Bird AC, Bressler NM, Bressler SB, et al. . An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367–74. - PubMed
    1. Age-Related Eye disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417–36. 10.1001/archopht.119.10.1417 - DOI - PMC - PubMed
    1. Age Related Eye Disease Study 2 Research Group. Lutein+zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005–15. 10.1001/jama.2013.4997 - DOI - PubMed
    1. Chakravarthy U, Harding SP, Rogers CA, et al. . Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399–411. 10.1016/j.ophtha.2012.04.015 - DOI - PubMed

Publication types